SFM
TXMD icon

Signet Financial Management’s TherapeuticsMD TXMD Stock Holding History

Signet Financial Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-99
Closed -$24K – 1111
2018
Q1 		$24K Buy
+99
New +$27.8K ﹤0.01% 454

Other funds holding TXMD

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Signet Financial Management's TXMD Position: Q2 2018 in Review

Signet Financial Management sold out of TherapeuticsMD (TXMD) in Q2 2018, closing a stake of 99 shares — an estimated $24K sold.

Signet Financial Management first reported a position in TXMD in Q1 2018 and held it in 1 quarter. The position peaked at $24K in Q1 2018. 144 funds tracked by Wall St. Rank hold TXMD as of Q2 2018.

  • Signet Financial Management reported no remaining TherapeuticsMD position as of Q2 2018 after selling out during the quarter.
  • Signet Financial Management sold 99 TherapeuticsMD shares in Q2 2018, an estimated $24K.
  • Signet Financial Management first reported a position in TherapeuticsMD in Q1 2018 and held it in 1 quarter.
  • Signet Financial Management's TherapeuticsMD position peaked at $24K in Q1 2018.
  • 144 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2018.

Based on Signet Financial Management's 13F filing for Q2 2018, filed 10 Aug 2018.